ChemicalBook Product Catalog API Antineoplastic agents Antitumor Adjuvant Drugs 4-[(1E)-2-[[(4-Chlorophenyl)methyl]sulfonyl]ethenyl]-benzoic acid

4-[(1E)-2-[[(4-Chlorophenyl)methyl]sulfonyl]ethenyl]-benzoic acid

Product Name4-[(1E)-2-[[(4-Chlorophenyl)methyl]sulfonyl]ethenyl]-benzoic acid
CAS334969-03-8
MFC16H13ClO4S
MW336.79
EINECS
MOL File334969-03-8.mol

Chemical Properties

Boiling point	607.8±55.0 °C(Predicted)
Density	1.423±0.06 g/cm3(Predicted)
storage temp.	Store at -20°C
solubility	DMSO: 35.71 mg/mL (106.03 mM)
form	Solid
pka	4.00±0.10(Predicted)
color	White to off-white

Usage And Synthesis

Uses

Recilisib (ON 01210) is a radioprotectant, which can activate AKT, PI3K activities in cells[1].

Biological Activity

Recilisib is a radioprotectant that activates the activity of AKT and PI3K in cells.

in vivo

Recilisib Sodium (500 mg/kg) significantly increases the rate of recovery and differentiation of primitive bone marrow myeloid progenitor cells in mice. It in combination with radiation reduces CFU numbers in mice, but the Recilisib Sodium-treated mice consistently retain a capability to form differentiated colonies.

target

IC 50

PI3K

References

[1] Kang AD, et al. ON01210.Na (Ex-RAD) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013;8(3):e58355. DOI:10.1371/journal.pone.0058355

4-[(1E)-2-[[(4-Chlorophenyl)methyl]sulfonyl]ethenyl]-benzoic acid Supplier

4-[(1E)-2-[[(4-Chlorophenyl)methyl]sulfonyl]ethenyl]-benzoic acid manufacturers

Related Product Information

Send Inquriy

Akt

PI3K